Literature DB >> 11042193

Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes.

J B Petro1, W N Khan.   

Abstract

Mutations in the gene encoding Bruton's tyrosine kinase (BTK) interfere with B cell proliferation and lead to an X-linked immunodeficiency in mice characterized by reduced B cell numbers. Recent studies have established that BTK transmits signals from the B cell antigen receptor (BCR) to transcription factor NF-kappaB, which in turn reprograms a set of genes required for normal B cell growth. We now demonstrate that induction of NF-kappaB via this pathway requires the intermediate action of the -gamma2 isoform of phospholipase C (PLC-gamma2), a potential phosphorylation substrate of BTK. Specifically, pharmacologic agents that block the action of either PLC-gamma2 or its second messengers prevent BCR-induced activation of IkappaB kinase. Moreover, activation of NF-kappaB in response to BCR signaling is completely abolished in B cells deficient for PLC-gamma2. Taken together, these findings strongly suggest that PLC-gamma2 functions as an integral component of the BTK/NF-kappaB axis following BCR ligation. Interference with this NF-kappaB cascade may account for some of the B cell defects reported for plc-gamma2(-/-) mice, which develop an X-linked immunodeficiency-like phenotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042193     DOI: 10.1074/jbc.M009137200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

Review 2.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

Review 3.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

4.  Actin depolymerization transduces the strength of B-cell receptor stimulation.

Authors:  Shengli Hao; Avery August
Journal:  Mol Biol Cell       Date:  2005-02-23       Impact factor: 4.138

5.  Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I.

Authors:  Jaya Rajaiya; Jamee C Nixon; Neil Ayers; Zana P Desgranges; Ananda L Roy; Carol F Webb
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 6.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

Review 7.  Translational hematology.

Authors:  Klaus Geissler
Journal:  Wien Med Wochenschr       Date:  2014-09-10

8.  Bruton's tyrosine kinase promotes persistence of mature anti-insulin B cells.

Authors:  Rachel H Bonami; Allison M Sullivan; James B Case; Hannah E Steinberg; Kristen L Hoek; Wasif N Khan; Peggy L Kendall
Journal:  J Immunol       Date:  2014-01-22       Impact factor: 5.422

Review 9.  Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.

Authors:  W N Khan
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 10.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.